Ligand Pharmaceuticals Inc (LGND)
EBITDA
$274.03M
TTM · Period ending: · USD
LGND EBITDA
Latest reported$274.03Mperiod ending
Latest reported$274.03Mperiod ending
LGND TTM EBITDA (-$18.40M → $274.03M)
TTM EBITDA
High-resolution chart · PNG
LGND ebitda history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | EBITDA (USD) |
|---|---|
| 274,033,000 | |
| 222,412,000 | |
| 196,165,000 | |
| 100,071,000 | |
| -45,939,000 | |
| -122,106,000 | |
| 40,790,000 | |
| 97,138,000 | |
| 90,210,000 | |
| 158,429,000 | |
| 101,419,000 | |
| 141,001,000 | |
| 170,724,000 | |
| 181,524,000 | |
| 122,960,000 | |
| 63,803,000 | |
| 62,131,000 | |
| 62,312,000 | |
| 80,221,000 | |
| 95,714,000 | |
| 70,400,000 | |
| 85,023,000 | |
| 44,848,000 | |
| 44,967,000 | |
| 43,428,000 | |
| 2,731,000 | |
| 874,923,000 | |
| 818,879,000 | |
| 917,364,000 | |
| 992,693,000 | |
| 197,183,000 | |
| 268,105,000 | |
| 189,553,000 | |
| 130,593,000 | |
| 82,593,000 | |
| 67,512,000 | |
| 58,313,000 | |
| 50,869,000 | |
| 55,345,000 | |
| 44,790,000 | |
| 45,976,000 | |
| 44,423,000 | |
| 30,974,000 | |
| 29,895,000 | |
| 24,684,000 | |
| 21,618,000 | |
| 23,368,000 | |
| 19,792,000 | |
| 19,382,000 | |
| 19,926,000 | |
| 18,645,000 | |
| 16,660,000 | |
| 12,072,000 | |
| 7,635,000 | |
| 2,870,000 | |
| 4,976,000 | |
| 2,200,000 | |
| 3,463,000 | |
| 1,319,000 | |
| -10,143,000 | |
| -22,419,000 | |
| -24,759,000 | |
| -26,567,000 | |
| -21,461,000 | |
| -3,929,000 | |
| -4,786,000 | |
| -7,229,000 | |
| -78,499,000 | |
| -85,799,000 | |
| -87,768,000 | |
| -93,198,000 | |
| -30,653,000 | |
| -33,535,000 | |
| -41,330,000 | |
| -57,560,000 | |
| -42,300,000 | |
| -52,258,000 | |
| -52,255,000 | |
| -33,713,000 | |
| -37,197,000 | |
| -18,756,000 | |
| -7,114,000 | |
| -8,838,000 | |
| -37,217,000 | |
| -49,111,000 | |
| -62,804,000 | |
| -66,766,000 | |
| -28,253,000 | |
| -21,180,000 | |
| -11,234,000 | |
| -4,897,000 | |
| -23,338,000 | |
| -23,689,000 | |
| -25,915,000 | |
| -17,702,000 | |
| -14,709,000 | |
| -12,544,000 | |
| -10,618,000 | |
| -16,564,000 | |
| -30,598,000 |